Published: March 07, 2011
NanoLogix Provides 6-hour MRSA Results at UTHSC - Houston. Welcomes New Science Advisory Board Members
HUBBARD, Ohio - (BUSINESS WIRE) - NanoLogix
(OTC MARKETS: NNLX), a biotechnology innovator in the rapid
detection and identification of live-cell microorganisms, announces
preliminary results of MRSA (Methicillin-resistant Staphylococcus
aureus) testing at the University
of Texas Health Science Center - Houston. Dr. Jonathan Faro, M.D.,
Ph.D. has found NanoLogix technology is able to deliver results for MRSA
in 6 hours, as opposed to conventional culture-based testing wait times
of 24 to 48 hours. Dr. Faro is lead researcher in an ongoing Group B
Streptococcus (GBS) clinical trial using NanoLogix test kits at UTHSC.
Scientific papers detailing the first two phases of the GBS clinical
trial are currently being submitted for publication in peer-reviewed
journals.
An
interview with Dr. Faro explaining his rapid live-cell results can
be found at www.nanologix.com.
NanoLogix Announces New Science Advisory Board Members
NanoLogix is pleased to welcome four exceptionally talented individuals
to its Science Advisory Board. New members include Dr. Megan Barnhizer,
D.V.M.; Dr. Sebastian Faro, M.D., Ph.D.; and Dr. Allan Katz, M.D. and
Dr. Gwen R. Acker Wood, Ph.D., J.D. They join existing Science Board
members Ahmer Kodvawalla, M.S., M.B.A.; Hilda Diaz, M.S.; and Dr.
Clifford Watts, M.D.
"We are very pleased to welcome these new members to the Science
Advisory Board," said Bret Barnhizer, NanoLogix CEO. "The new members
add depth and valuable expertise to our SAB as the UTHSC - Houston
approaches the conclusion of our GBS clinical trial and we begin the
application process for FDA approval."
Dr. Allan Katz, M.D., professor and Vice-Chairman of Obstetrics and
Gynecology at the University of Texas Medical School in Houston, and
chief of Gynecology at Hermann Memorial Hospital in Houston stated, "We
have relied far too long on traditional culture based technology, and
this practice has undoubtedly contributed towards the development of
microbial resistance. The technology offered by NanoLogix is exciting as
it promises more rapid results in a time when it most matters to the
patient. It also holds vast potential as the technology extends beyond
GBS and MRSA and tests can be performed by almost anyone, in any corner
of the world."
Dr. Sebastian Faro, M.D., Chief of Obstetrics and Gynecology at LBJ
Hospital in Houston, Texas, said, "This is an extremely exciting time to
be working on the development of diagnostic tests to identify pathogenic
bacteria in a rapid manner. This technology from NanoLogix will
revolutionize the process of identifying disease causing bacteria and
facilitate a more direct approach in choosing appropriate antibiotic
therapy."
NanoLogix New Science Advisory Board Members
Megan Barnhizer, D.V.M.
Dr. Megan Barnhizer has been a veterinarian in clinical practice since
graduating from the Ohio State University College of Veterinary Medicine
in 1999. Her addition to the Science Advisory Board comes at a time of
marked increase in interest in NanoLogix detection and diagnostic
technologies from international and domestic corporations, agencies and
organizations with a focus on livestock and animal husbandry.
Sebastian Faro, M.D., Ph.D.
Dr. Sebastian Faro brings an extensive body of knowledge concerning
obstetrics, gynecology, and infectious diseases to the NanoLogix Science
Advisory Board. Dr. Faro is Chief of Obstetrics and Gynecology at LBJ
Hospital in Houston, Texas. He is also the current Vice-Chair of the
Obstetrics, Gynecology, and Reproductive Sciences Department at the
University of Texas Health Science Center in Houston. Dr. Faro has
published at least 149 articles in peer-reviewed medical publications
and served as Editor-in-Chief of the Infectious Diseases in Obstetrics
and Gynecology journal for 13 years.
Allan Katz, M.D.
Dr. Allan Katz brings to the advisory board over forty years of
experience in the fields of women's health and pregnancy, including the
management of high risk pregnancies. Dr. Katz is a Robert K. Creasy
Professor and Vice-Chairman of Obstetrics and Gynecology at the
University of Texas Medical School at Houston. Dr. Katz is also Chief of
Gynecology at Hermann Memorial Hospital.
Gwen R. Acker Wood, Ph.D. J.D.
Gwen R. Acker Wood is a U.S. and foreign patent attorney, who brings a
wealth of medical, biotechnology and life sciences patent experience to
NanoLogix. Dr. Wood handles patent filings for NanoLogix through her
firm, Acker Wood IP Law. Prior to becoming a patent attorney, Dr. Wood
was a research scientist in the areas of neurochemistry and
psychoimmunology. In addition, she served as an adjunct professor of
biology, nutritional science and advanced pathophysiology at New York
University, as well as adjunct professor of biology and advanced
pathophysiology at Duquesne University.
More information on the Nanologix Science Advisory Board can be found here
or by going to http://www.nanologix.com/team.html#Science%20Advisory%20Board%20Members.
NanoLogix General Shareholder Meeting Rescheduled
The NanoLogix general shareholder meeting is being rescheduled and will
be held in the middle of September 2011. Additional details concerning
the date and time of the meeting will be announced as September grows
closer. This shareholder meeting will be held virtually, through the
Broadridge Virtual Shareholder Meeting service. Further information
regarding the process can be found at http://www.broadridge.com/vsm/.
About NanoLogix, Inc.
NanoLogix is a biotechnology company focused primarily on rapid
diagnostics. Its products offer accelerated detection and identification
of microorganisms. In addition to medical and homeland security
applications, NanoLogix technology is applicable in pharmaceutical,
industrial, veterinary and environmental testing. Patents granted to
NanoLogix can be used in the areas of applied microbiology, soil
microbiology and bioremediation, microbial physiology, molecular
biology, pharmacology, pharmaco-kinetics, and antibiotic sensitivity.
For more information visit www.nanologix.com.
This press release contains statements, which may constitute "forward-
looking statements" within the meaning of the Securities Act of 1933 and
the Securities Exchange Act of 1934, as amended by the Private
Securities Litigation Reform Act of 1995. Those statements include
statements regarding the intent, belief or current expectations of
NanoLogix, Inc., and members of its management as well as the
assumptions on which such statements are based. Prospective investors
are cautioned that any such forward-looking statements are not
guarantees of future performance and involve risks and uncertainties,
and that actual results may differ materially from those contemplated by
such forward-looking statements. The Company undertakes no obligation to
update or revise forward-looking statements to reflect changed
assumptions, the occurrence of unanticipated events or changes to future
operating results.
Media Contact:
Technica Communications
Lisa Ann Pinkerton,
650-288-1824
Lisaann@technicacommunications.com
or
Investor
Contact:
NanoLogix, Inc.
Carol Surrena, 330-534-0800
carol@nanologix.com
Copyright © 2012, Business Wire, Inc., All rights reserved.
Copyright © 2012, NewsBlaze,
Daily News
Search News
